

Date: 16, 2006.

John C. Dugan,
Comptroller of the Currency.

B / B / G
F / , 28, 2006.

Jennifer J. Johnson,
Secretary of the Board.

D / , DC, 29 /
/ , 2006.

F / D / I / C /

Robert E. Feldman,
Executive Secretary.

D / : F / 24, 2006.
B /

John M. Reich,
Director.

F / D / .06 3179 F / 4 3 06; 8:45 /

BILLING CODE 4810-33-P; 6210-01-P; 6714-01-P;
6720-01-P

FEDERAL RESERVE SYSTEM

Sunshine Act Meeting

AGENCY HOLDING THE MEETING: B /
G / F /

TIME AND DATE: 11:30 / ,
A / 10, 2006

PLACE: / E / F /
B / B / , 20 / C
/ , D.C. 20551.

STATUS: C

MATTERS TO BE CONSIDERED:

1. / (/)
/)
F /
2. A /

FOR FURTHER INFORMATION CONTACT:

/ D / D /
/ A / B /
B / 202 452 2955.

SUPPLEMENTARY INFORMATION:

/ 202 452 3206 /
/ 5 /
/ I " A DA
(/)
B / (/ B /)
(a)
B / I A DA / I.
/ 30
(/) / FDA
/ A DA
A /

B / G / F /
31, 2006.

Robert deV. Frierson,
Deputy Secretary of the Board.

F / D / .06 3276 F / * (/)

FOR FURTHER INFORMATION CONTACT:

/ A / G / C /
/ 600 /
A / , DC 20580;
(202) 326 2155.

SUPPLEMENTARY INFORMATION: I

A / (FDA)
/ H / A /
FDA /
FDA /
D / A / (DA) / FDA
/ A / (A DA)

/ H / A /
/ I " A DA
(/)
B / (/ B /)
(a)
B / I A DA / I.
/ 30
(/) / FDA
/ A DA
A /

¹C 4.2(), 16 CF 4.2()

FDA
 A DA E0- 1.11438, * Df D(0 /- 0 E0- 108 0 91 1. 8, (20 6 1.633748 0 2.) 90
 0
 Df 0-1.1 D 0 E0-) * f a f f 0 . () (

⁴ A J & J, E. B., *et al.*, 2005
 D., *et al.*, 1990

⁵ See C. D., G., (9, 2005).

⁶ See C. D., H. A., (13, 2005).

⁷ I. 2002
 C. H.
 F. C., *Generic Drug Entry Prior to Patent Expiration: An FTC Study* (J 2002), available at <http://www.ftc.gov/os/2002/07/genericdrugstudy.pdf> (G. D.).

² 2003
 I. 108 173)
 FDA
 (1)
 (2)
 ()
³ Teva Pharm. Indus., FDA, 410 F.3 51 (DC C 2005).

⁸ 1999
 1998, FDA 180-
 Mova, Shalala, 140 F.3 1060 (DC C 1998).
 FDA 180-
 Generic Drug Study 57.

